Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9Y234

UPID:
LIPT_HUMAN

ALTERNATIVE NAMES:
Lipoate biosynthesis protein; Lipoate-protein ligase; Lipoyl ligase

ALTERNATIVE UPACC:
Q9Y234; Q4ZFZ1

BACKGROUND:
The protein Lipoyltransferase 1, mitochondrial, functions as a key enzyme in lipoic acid metabolism, facilitating the attachment of lipoyl groups to specific enzymes. This process is vital for the proper functioning of mitochondrial energy metabolism.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Lipoyltransferase 1 could open doors to potential therapeutic strategies for treating Lipoyltransferase 1 deficiency, a condition leading to severe metabolic complications. Exploring its function further may reveal novel targets for drug development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.